



- (51) International Patent Classification:
C07K 16/28 (2006.01) A61K 39/395 (2006.01)
- (21) International Application Number:
PCT/US2015/054490
- (22) International Filing Date:
7 October 2015 (07.10.2015)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/062,431 10 October 2014 (10.10.2014) US
- (71) Applicant: MEDIMMUNE, LLC [US/US]; One Medimmune Way, Gaithersburg, MD 20878 (US).
- (72) Inventors: HAMMOND, Scott A.; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US). OBERST, Michael; c/o Medimmune, LLC, One

Medimmune Way, Gaithersburg, MD 20878 (US). DU, Qun; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US). DAMSCHRODER, Melissa; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US).

(74) Agents: MENSAH, Kwame N. et al.; Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

- (54) Title: HUMANIZED ANTI-OX40 ANTIBODIES AND USES THEREOF

FIGURE 1

9B12VH mutant variants pairing with humanized VL											
Clone ID	VH mutant (nick name)	VH mutation position							Removing Sequence liabilities		
		27D	39K	47Y	48M	71R	78Y	91F	NG (CDR2H)	RYDYDG (CDR3H)	
OX40mAb1	9B12 chimera	D	K	Y	M	R	Y	F			
OX40mAb2	9B12 mouse VH	D	K	Y	M	R	Y	F			
OX40mAb5	hu	G	Q	W	I	P	F	Y	NG	RYDYDG	
OX40mAb8	huKR	G	K	W	I	R	F	Y			
OX40mAb10	m1	D	Q	W	I	P	F	Y			
OX40mAb11	m2	G	K	Y	M	P	F	Y			
OX40mAb12	m3	G	Q	W	I	R	Y	F			
OX40mAb13	KR-DYMYF	D	K	Y	M	R	Y	F			
OX40mAb14	KR-DYIYF	D	K	Y	I	R	Y	F			
OX40mAb15	KR-DYIFF	D	K	Y	I	R	F	F			
OX40mAb16	KR-DYIYY	D	K	Y	I	R	Y	Y			
OX40mAb17	KR-DYIFY	D	K	Y	I	R	F	Y			
OX40mAb18	KYYF	G	K	Y	I	R	Y	F			
OX40mAb19	KYRYF	G	K	Y	I	R	Y	F			
OX40mAb20	KYRY	G	K	Y	I	R	Y	Y	NG	RYDYDG	
OX40mAb21	KYY	G	K	Y	I	R	Y	Y			
OX40mAb22	55A,96K-A	G	K	Y	I	R	Y	Y	NA	KYDYDG	
OX40mAb23	55A	G	K	Y	I	R	Y	Y	NA	RYDYDG	
OX40mAb24	96K	G	K	Y	I	R	Y	Y	NG	KYDYDG	
OX40mAb25	54S	G	K	Y	I	R	Y	Y	SG	RYDYDG	
OX40mAb25a	54S,96K	G	K	Y	I	R	Y	Y	SG	KYDYDG	
OX40mAb26	mouseVH-55A	D	K	Y	M	R	Y	F	NA	RYDYDG	
OX40mAb27	55A,96K	G	K	Y	I	R	Y	Y	NA	KYDYDG	
OX40mAb28	huIgG4P	G	K	Y	I	R	Y	Y	NG	KYDYDG	
OX40mAb29	huIgG1TM	G	K	Y	I	R	Y	Y	NG	KYDYDG	
OX40mAb30	mlgG1	G	K	Y	I	R	Y	Y	NG	KYDYDG	
OX40mAb31	huIgG4P	G	K	Y	I	R	Y	Y	NA	KYDYDG	
OX40mAb32	huIgG1TM	G	K	Y	I	R	Y	Y	NA	KYDYDG	
OX40mAb37	mlgG1	G	K	Y	I	R	Y	Y	NA	KYDYDG	

(57) Abstract: The disclosure provides humanized anti-OX40 antibodies. Also provided are methods of making such antibodies, and methods of use, e.g., treatment of cancer.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available):* ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*